Covid-19 Vaccine India: The Russian Direct Investment Fund (RDIF) and Indian drug company Panacea Biotec announced the launch of the Corona virus vaccine Sputnik V in India on Monday. The first fleet production of the COVID-19 vaccine will be produced by Panacea Biotech at Baddi in Himachal Pradesh and will be sent to the Gamaleya Center in Russia for quality control.
Indian firm Panacea Biotec begins production of Sputnik V vaccines. It will annually manufacture 100 million doses of Sputnik V.
Video source: Russian Direct Investment Fund (RDIF) pic.twitter.com/zX070h08Cc
– ANI (@ANI) May 24, 2021
Company said important steps in the fight against pandemic
RDIF and Panacea Biotech said in a joint statement that large-scale production of the vaccine is expected to begin this summer. It further states that as announced in April, RDIF and Panacea have agreed to produce Sputnik V 100 million or 100 million doses per year. Kirill Dmitriev, chief executive of RDIF, said that the launch of production in India under the agreement with Panacea Biotec is an important step in helping the country fight against the epidemic.
Yaas turns into a severe cyclonic storm, Home Minister Amit Shah holds meeting with Chief Ministers of Odisha, Andhra, West Bengal
He further said that production of Sputnik V will support India’s authorities in trying to overtake this dangerous phase of the corona virus as soon as possible, while preventing the vaccine from spreading to other countries around the world. Will also be exported to On this, Rajesh Jain, MD of Panacea Biotech said that this is an important step as we are starting the production of Sputnik V. He said that together with RDIF, he hopes to give back the feeling of normalcy to people across the country and the world.
Sputnik V was registered under Emergency Use Authorization in India on 12 April 2021 and vaccination against the Corona virus began on 14 May with the Russian vaccine.